PD-1 inhibitor and anti-VEGF monoclonal antibody

This page covers all PD-1 inhibitor and anti-VEGF monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and VEGF-A.

Targets

PD-1 and VEGF-A

Phase 2 pipeline (1)

• Bevacizumab Biosimilar IBI305 plus sintilimab · Ze-yang Ding, MD · Oncology
  Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

Patent intelligence

• pd 1 inhibitor and anti vegf monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates